Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
11 Dezembro 2023 - 2:50PM
Business Wire
Natera successfully achieves key objective for
trial set to begin on Jan. 22nd
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
testing, today announced that the United States District Court for
the District of Delaware has issued an order denying CareDx’s
motion for summary judgment on two Natera patents in the
infringement lawsuit filed by Natera against CareDx.
The Court has ruled that two of the patents asserted by Natera
against CareDx will proceed to trial. The trial will commence on
January 22, 2024.
The company stated: “We are gratified that the Court has issued
a decision that provides a clear path to trial as we work to
protect our significant investments in innovation from unlawful
infringement.”
As previously disclosed, Natera successfully invalidated all
three of CareDx’s patents that were asserted against Natera in a
related case.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 150 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
developments in matters under dispute or litigation, the scope of
protection we establish and maintain for, and developments or
disputes concerning, our intellectual property or other proprietary
rights, and our expectations of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in “Risk
Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231211868061/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024